NASDAQ:ABSI

Absci Stock News

Healthcare > Biotechnology

Buy ABSI

*Your capital is at risk

$5.94

-0.410 (-6.46%)

At Close: Jun 03, 2026

ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study

11:41am, Friday, 05'th Dec 2025

Absci Corporation stock jumps after initiating dosing in its phase I/IIa ABS-201 study for androgenetic alopecia, seeking early safety and efficacy signals.

Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia

08:00am, Thursday, 04'th Dec 2025

Study to evaluate safety and efficacy of novel anti-PRLR antibody; interim data anticipated in the second half of 2026 Trial design leverages operational synergies to enable accelerated registrational

10 AI Stocks Worth Buying Right Now

05:45am, Thursday, 04'th Dec 2025

Artificial intelligence (AI) will reshape industries for decades, making early positioning in focused AI players critical. Smaller AI companies often offer more upside than megacaps that have already

Miss These Genesis Mission Stocks, and You’ll Regret It for a Decade

12:00am, Monday, 01'st Dec 2025

The government is taking equity stakes in American companies. Here are the next Genesis Mission stocks to buy before the capital hits.

Absci Corporation (ABSI) Presents at Jefferies London Healthcare Conference 2025 Transcript

07:23pm, Friday, 21'st Nov 2025

Absci Corporation ( ABSI ) Jefferies London Healthcare Conference 2025 November 18, 2025 4:30 AM EST Company Participants Sean McClain - Founder, CEO, President & Director Presentation Operator It's m

Absci Corporation (ABSI) Q3 2025 Earnings Call Transcript

10:31pm, Wednesday, 12'th Nov 2025

Absci Corporation ( ABSI ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Alexander Khan - VP of Finance & Head of Investor Relations Sean McClain - Founder, CEO, President &

Absci Corporation (ABSI) Reports Q3 Loss, Lags Revenue Estimates

06:26pm, Wednesday, 12'th Nov 2025

Absci Corporation (ABSI) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.24 per share a year ago.

Absci Reports Business Updates and Third Quarter 2025 Financial and Operating Results

04:05pm, Wednesday, 12'th Nov 2025

Reported interim results for Phase 1 trial for ABS-101 (anti-TL1A) On track to initiate Ph1/2a trial for ABS-201 (anti-PRLR for androgenetic alopecia) in December; hosting KOL seminar on December 11 E

Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025

04:05pm, Wednesday, 29'th Oct 2025

VANCOUVER, Wash. and NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today announced the comp

Absci to Participate in Upcoming Investor Conferences

08:00am, Monday, 27'th Oct 2025

VANCOUVER, Wash. and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today announ

Absci to Host KOL Seminar on ABS-201 Androgenetic Alopecia Program on December 11, 2025; Announces Accelerated Initiation of Phase 1/2a Trial

08:00am, Wednesday, 15'th Oct 2025

Webinar on December 11 to feature leading KOLs in dermatology and hair loss alongside Absci leadership Phase 1/2a trial now expected to begin in December 2025, ahead of prior guidance VANCOUVER, Wash.

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by